Toxicities related to surgery (grade ≥2), radiotherapy, and chemotherapy (grade ≥3) per treatment group
| Boosting (n=101) | Debulking (n=60) | Neither (n=29) | p-value | |
| Surgery | ||||
| Intraoperative injury | – | 2 (3%) | – | |
| Infection | – | 4 (7%) | – | |
| IC-admission | – | 1 (2%) | – | |
| Blood transfusion | – | 1 (2%) | – | |
| Total† | – | 8 | – | |
| Total patients | – | 6 (10%) | – | |
| Radiotherapy | ||||
| Urological | 3 (3%) | – | 2 (7%) | 0.10 |
| Gastrointestinal | 9 (9%) | 5 (8%) | 6 (21%) | 0.19 |
| Genital | 1 (1%) | – | 1 (4%) | 0.38 |
| Other | 2 (2%) | 2 (3%) | 2 (7%) | 0.30 |
| Total† | 15 | 5 | 2 | |
| Total patients | 15 (15%) | 7 (12%) | 7 (24%) | 0.29 |
| Chemotherapy | ||||
| Nausea/vomiting | 3 (3%) | 3 (5%) | – | 0.62 |
| Nephrotoxicity | 4 (4%) | 1 (2%) | – | 0.57 |
| Ototoxicity | 1 (1%) | – | – | |
| Bone marrow depression | – | 4 (7%) | 1 (3%) | 0.022* |
| Malaise/fatigue | – | 2 (3%) | 1 (3%) | 0.14 |
| Neurotoxicity | 1 (1%) | – | – | |
| Other | 3 (3%) | 3 (5%) | 3 (10%) | 0.19 |
| Total† | 12 | 4 | 9 | |
| Total patients | 9 (9%) | 11 (18%) | 5 (17%) | 0.16 |
| Total adverse events | ||||
| Total† | 27 | 17 | 11 | |
| Total patients | 21 (21%) | 21 (35%) | 11 (38%) | 0.06 |
*Statistically significant.
†Some patients experienced multiple toxicities.
IC, intensive care.;